Retracted: Gender Differences in Alcohol Treatment

Blendberg, J Molly; Àrnadottir, Svanlaug; Tarp, Kristine; Bilberg, Randi

doi:10.1093/alcalc/agaa071

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relapse (n = 110) was defined as return to any alcohol consumption during the 3 months of acamprosate treatment, whereas non-relapse (n = 157) was defined as abstinence from alcohol (no alcohol use) during 3 months of acamprosate treatment (see Figure 1a). Baseline characteristics of the AUD participants in both groups are listed in AUD participants, two thirds were men, consistent with most studies of AUD-a disorder that displays a striking difference in incidence between the sexes (Blendberg et al, 2020;Erol & Karpyak, 2015).…”

Section: Characteristics Of Study Participantssupporting

confidence: 78%

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study

Ho¹,

Zhang²,

Wei³

et al. 2022

British J Pharmacology

View full text Add to dashboard Cite

Background and Purpose Acamprosate is an anti‐craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety and those who relapsed, to determine whether those differences provide insight into variation in acamprosate treatment response phenotypes. Experimental Approach We previously conducted an acamprosate trial involving 442 AUD patients, and 267 of these subjects presented themselves for a 3‐month follow‐up. The primary outcome was abstinence. Clinical information, genomic data and metabolomics data were collected. Baseline plasma samples were assayed using targeted metabolomics. Key Results Baseline plasma arginine, threonine, α‐aminoadipic acid and ethanolamine concentrations were associated with acamprosate treatment outcomes and baseline craving intensity, a measure that has been associated with acamprosate treatment response. We next applied a pharmacometabolomics‐informed genome‐wide association study (GWAS) strategy to identify genetic variants that might contribute to variations in plasma metabolomic profiles that were associated with craving and/or acamprosate treatment outcome. Gene expression data for induced pluripotent stem cell‐derived forebrain astrocytes showed that a series of genes identified during the metabolomics‐informed GWAS were ethanol responsive. Furthermore, a large number of those genes could be regulated by acamprosate. Finally, we identified a series of single nucleotide polymorphisms that were associated with acamprosate treatment outcomes. Conclusion and Implications These results serve as an important step towards advancing our understanding of disease pathophysiology and drug action responsible for variation in acamprosate response and alcohol craving in AUD patients.

show abstract

Section: Characteristics Of Study Participantssupporting

confidence: 78%

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study

Ho¹,

Zhang²,

Wei³

et al. 2022

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…Third, this study only included male patients. Nevertheless, some studies have found sex differences in drinking behavior, neural systems, and AUD treatment ( 65 , 66 ). Schulte et al.…”

Section: Discussionmentioning

confidence: 99%

The effects of BDNF rs6265 and FGF21 rs11665896 polymorphisms on alcohol use disorder-related impulsivity in Han Chinese adults

Yang,

Wang,

Sun

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

IntroductionPatients with alcohol use disorder (AUD) often experience repeated withdrawal. Impulsivity is the most relevant factor influencing successful withdrawal. Brain-derived neurotrophic factor (BNDF) and fibroblast growth factor 21 (FGF21) are associated with impulsivity. Previous studies on the differential effects of BDNF or FGF21 on impulsivity have focused on single-gene effects and have inconsistent results. We aim to investigate the effects of BDNF rs6265 and FGF21 rs11665896, individually and together, on impulsivity during alcohol withdrawal in patients with AUD.MethodsWe recruited 482 adult Han Chinese males with AUD and assessed their impulsivity using the Barratt Impulsivity Scale. Genomic DNA was extracted and genotyped from peripheral blood samples. Statistical analysis was conducted on the data.ResultsThe T-test and 2 × 2 analysis of variance were used to investigate the effects of the genes on impulsivity. There was a significant BDNF × FGF21 interaction on no-planning impulsiveness (F = 9.15, p = 0.003, η2p = 0.03). Simple main effects analyses and planned comparisons showed that BDNF rs6265 A allele × FGF21 rs11665896 T allele was associated with higher no-planning impulsiveness. Finally, hierarchical regression analyses revealed that only the interaction of BDNF and FGF21 accounted for a significant portion of the variance in no-planning impulsiveness.Conclusion and significanceThe combination of BDNF rs6265 A allele and FGF21 rs11665896 T allele may increase impulsivity and discourage alcohol withdrawal. Our study provides a possible genetic explanation for the effects of associated impulsivity in patients with AUD from the perspective of gene-gene interactions.

show abstract

Retracted: Gender Differences in Alcohol Treatment

Cited by 2 publications

References 29 publications

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study

Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study

The effects of BDNF rs6265 and FGF21 rs11665896 polymorphisms on alcohol use disorder-related impulsivity in Han Chinese adults

Contact Info

Product

Resources

About